First Wave to merge with ImmunogenX; Caliway raises $100M; New deals for Replay’s Syena
First Wave BioPharma’s merger plans: The Florida biotech said it plans to merge with ImmunogenX, another gastrointestinal diseases company that is developing an oral candidate known as latiglutenase for celiac disease. After the deal closes, First Wave said it expects to announce that a global drugmaker is paying for the commercial rights to the drug candidate as well as new financing from undisclosed institutional investors. The Phase III trials are expected to begin in the second half of next year. — Kyle LaHucik
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.